BSc University of Kent in biochemistry and then a PhD from Warwick University which was sponsored by BP who were interested in ways to use bacteria in their industry. This was right at the start of the biotech revolution.

Stephen then did 15 years in biotech R&D in ICI/Zeneca much of the time developing ways to use enzymes to make fine chemicals, especially chiral agchem and pharma intermediates.

In 1996 Stephen moved into BD/commercial and was a founder and leader of the CDMO Avecia which was acquired by Merck/MSD and subsequently divested to Fujifilm. Stephen was SVP Commercial for Fujifilm Diosynth now a major global biologics business .

Stephen has been a strong voice for growing the UK as a powerhouse of biologics development and manufacture. He served on numerous government/industry teams, was Chair of bioProcessUK and elected to the BIA board. Stephen was the first recipient of the Peter Dunnill Award.

Stephen retired from Fujifilm in 2016 and then advised biotech companies with commercial and manufacturing challenges. He worked with the University of Warwick to spin out a new biotech NanoSyrinx (www.nanosyrinx.com) with proprietary technology for delivering therapeutic proteins and peptides to the interior of cells. NanoSyrinx received its first funding in 2020 with Stephen as its Chair. The company recently completed a further substantial investment round and after 4 years, Stephen has stepped down as Chair.